• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

The efficacy of new drug regimens in treating newly diagnosed high-risk cytogenetic multiple myeloma patients: a systematic literature review and meta-analysis

by MM360 Staff | May 28, 2025 | Publications

Front Med (Lausanne). 2025 May 13;12:1575914. doi: 10.3389/fmed.2025.1575914. eCollection 2025. ABSTRACT INTRODUCTION: Multiple myeloma (MM) is a plasma cell malignancy comprising 10% of hematologic cancers, associated with bone marrow dysfunction and organ damage....

Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies

by MM360 Staff | May 27, 2025 | Publications

Blood Cancer J. 2025 May 26;15(1):104. doi: 10.1038/s41408-025-01312-x. ABSTRACT While observation is the current standard of care for smoldering multiple myeloma (sMM), emerging evidence suggests that early therapeutic intervention may delay progression and improve...

Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review

by MM360 Staff | May 24, 2025 | Publications

Clin Lymphoma Myeloma Leuk. 2025 Apr 3:S2152-2650(25)00105-3. doi: 10.1016/j.clml.2025.03.013. Online ahead of print. ABSTRACT PURPOSE: The increasing use of single-arm and nonrandomized trial designs in oncology aims to expedite patient access to novel treatments. To...

Optimal daratumumab-based regimen for patients with newly diagnosed and previously untreated multiple myeloma: systematic review and component network meta-analysis

by MM360 Staff | May 17, 2025 | Publications

Syst Rev. 2025 May 16;14(1):113. doi: 10.1186/s13643-025-02804-4. ABSTRACT BACKGROUND: Daratumumab (Dara)-based regimens have been investigated in randomized controlled trials (RCTs) involving patients with newly diagnosed and previously untreated multiple myeloma...

Sarcopenia and clinical outcomes in lymphoma and multiple myeloma patients receiving hematopoietic cell transplantation: a systematic review and meta-analysis

by MM360 Staff | May 13, 2025 | Publications

Int J Hematol. 2025 May 13. doi: 10.1007/s12185-025-03998-y. Online ahead of print. ABSTRACT BACKGROUND: Sarcopenia, characterized by skeletal muscle loss, is increasingly recognized as a predictor of poor outcomes in hematologic malignancies. This study evaluated the...

Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis

by MM360 Staff | May 12, 2025 | Publications

Front Immunol. 2025 Apr 25;16:1565407. doi: 10.3389/fimmu.2025.1565407. eCollection 2025. ABSTRACT BACKGROUND: Multiple myeloma (MM) is a hematological malignancy with limited treatment options for patients with relapsed/refractory MM (RRMM). Teclistamab, a B-cell...
« Older Entries
Next Entries »

Recent Content

  • Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma
  • A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
  • Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma
  • Multiple Myeloma: Key Insights on Diagnosis and Evolving Treatment Strategies
  • Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
  • Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab
  • Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study
  • The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma
  • What Does Multiple Myeloma Mean?
  • FDA Update: Darzalex Faspro Not Approved for Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT